Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant gemcitabine + erlotinib + oxaliplatin followed by chemoradiotherapy with gemcitabine + erlotinib in borderline resectable pancreatic adenocarcinoma
2010-021872-27Phase 2Terminated
- Sponsor
- Institut Català d'Oncologia
- Start
- Nov 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib, gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Institut Català d'Oncologia. Primary endpoint: Tumor resectability rate after combined neoadjuvant treatment. Started Nov 2010; status: terminated.
02
Drugs
erlotinibgemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-021872-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021872-27.